View Future GrowthOrient Pharma 過去の業績過去 基準チェック /46Orient Pharmaは、平均年間74.9%の収益成長を遂げていますが、 Pharmaceuticals業界の収益は、年間 成長しています。収益は、平均年間9.9% 26.8%収益成長率で 成長しています。 Orient Pharmaの自己資本利益率は7.6%であり、純利益率は13.9%です。主要情報74.91%収益成長率75.42%EPS成長率Pharmaceuticals 業界の成長18.53%収益成長率26.76%株主資本利益率7.55%ネット・マージン13.90%前回の決算情報31 Mar 2026最近の業績更新Reported Earnings • May 16First quarter 2026 earnings released: EPS: NT$0.17 (vs NT$0.23 in 1Q 2025)First quarter 2026 results: EPS: NT$0.17 (down from NT$0.23 in 1Q 2025). Revenue: NT$331.2m (up 4.5% from 1Q 2025). Net income: NT$38.7m (down 23% from 1Q 2025). Profit margin: 12% (down from 16% in 1Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 81% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.Reported Earnings • Mar 14Full year 2025 earnings released: EPS: NT$0.90 (vs NT$0.48 in FY 2024)Full year 2025 results: EPS: NT$0.90 (up from NT$0.48 in FY 2024). Revenue: NT$1.40b (up 14% from FY 2024). Net income: NT$208.4m (up 94% from FY 2024). Profit margin: 15% (up from 8.8% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.Reported Earnings • Nov 15Third quarter 2025 earnings released: EPS: NT$0.21 (vs NT$0.023 in 3Q 2024)Third quarter 2025 results: EPS: NT$0.21 (up from NT$0.023 in 3Q 2024). Revenue: NT$316.1m (up 2.0% from 3Q 2024). Net income: NT$47.3m (up NT$42.1m from 3Q 2024). Profit margin: 15% (up from 1.7% in 3Q 2024). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 93% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.Reported Earnings • Aug 17Second quarter 2025 earnings released: EPS: NT$0.08 (vs NT$0.26 in 2Q 2024)Second quarter 2025 results: EPS: NT$0.08 (down from NT$0.26 in 2Q 2024). Revenue: NT$325.5m (flat on 2Q 2024). Net income: NT$18.8m (down 68% from 2Q 2024). Profit margin: 5.8% (down from 18% in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 99% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth.Reported Earnings • Jul 02First quarter 2025 earnings released: EPS: NT$0.23 (vs NT$0.22 in 1Q 2024)First quarter 2025 results: EPS: NT$0.23 (up from NT$0.22 in 1Q 2024). Revenue: NT$316.9m (up 5.1% from 1Q 2024). Net income: NT$50.6m (up 4.3% from 1Q 2024). Profit margin: 16% (in line with 1Q 2024). Over the last 3 years on average, earnings per share has increased by 109% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth.Reported Earnings • Mar 26Full year 2024 earnings released: EPS: NT$0.48 (vs NT$0.10 in FY 2023)Full year 2024 results: EPS: NT$0.48 (up from NT$0.10 in FY 2023). Revenue: NT$1.22b (up 37% from FY 2023). Net income: NT$107.4m (up 382% from FY 2023). Profit margin: 8.8% (up from 2.5% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 115% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth.すべての更新を表示Recent updatesReported Earnings • May 16First quarter 2026 earnings released: EPS: NT$0.17 (vs NT$0.23 in 1Q 2025)First quarter 2026 results: EPS: NT$0.17 (down from NT$0.23 in 1Q 2025). Revenue: NT$331.2m (up 4.5% from 1Q 2025). Net income: NT$38.7m (down 23% from 1Q 2025). Profit margin: 12% (down from 16% in 1Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 81% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.Reported Earnings • Mar 14Full year 2025 earnings released: EPS: NT$0.90 (vs NT$0.48 in FY 2024)Full year 2025 results: EPS: NT$0.90 (up from NT$0.48 in FY 2024). Revenue: NT$1.40b (up 14% from FY 2024). Net income: NT$208.4m (up 94% from FY 2024). Profit margin: 15% (up from 8.8% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.お知らせ • Feb 26Orient Pharma Co., Ltd., Annual General Meeting, Jun 16, 2026Orient Pharma Co., Ltd., Annual General Meeting, Jun 16, 2026. Location: 13 floor no,128, sec.6 ch`eng to rd., beitou district, taipei city TaiwanReported Earnings • Nov 15Third quarter 2025 earnings released: EPS: NT$0.21 (vs NT$0.023 in 3Q 2024)Third quarter 2025 results: EPS: NT$0.21 (up from NT$0.023 in 3Q 2024). Revenue: NT$316.1m (up 2.0% from 3Q 2024). Net income: NT$47.3m (up NT$42.1m from 3Q 2024). Profit margin: 15% (up from 1.7% in 3Q 2024). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 93% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Sep 08Investor sentiment improves as stock rises 23%After last week's 23% share price gain to NT$28.25, the stock trades at a trailing P/E ratio of 79x. Average trailing P/E is 17x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 25% over the past three years.New Risk • Sep 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.4% average weekly change). Profit margins are more than 30% lower than last year (6.3% net profit margin).Valuation Update With 7 Day Price Move • Aug 22Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to NT$26.25, the stock trades at a trailing P/E ratio of 73.5x. Average trailing P/E is 16x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 19% over the past three years.Reported Earnings • Aug 17Second quarter 2025 earnings released: EPS: NT$0.08 (vs NT$0.26 in 2Q 2024)Second quarter 2025 results: EPS: NT$0.08 (down from NT$0.26 in 2Q 2024). Revenue: NT$325.5m (flat on 2Q 2024). Net income: NT$18.8m (down 68% from 2Q 2024). Profit margin: 5.8% (down from 18% in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 99% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth.Reported Earnings • Jul 02First quarter 2025 earnings released: EPS: NT$0.23 (vs NT$0.22 in 1Q 2024)First quarter 2025 results: EPS: NT$0.23 (up from NT$0.22 in 1Q 2024). Revenue: NT$316.9m (up 5.1% from 1Q 2024). Net income: NT$50.6m (up 4.3% from 1Q 2024). Profit margin: 16% (in line with 1Q 2024). Over the last 3 years on average, earnings per share has increased by 109% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Jun 09Investor sentiment improves as stock rises 16%After last week's 16% share price gain to NT$36.95, the stock trades at a trailing P/E ratio of 76.8x. Average trailing P/E is 19x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 89% over the past three years.New Risk • Apr 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 9.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.Valuation Update With 7 Day Price Move • Apr 07Investor sentiment deteriorates as stock falls 26%After last week's 26% share price decline to NT$26.00, the stock trades at a trailing P/E ratio of 54x. Average trailing P/E is 18x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 31% over the past three years.Reported Earnings • Mar 26Full year 2024 earnings released: EPS: NT$0.48 (vs NT$0.10 in FY 2023)Full year 2024 results: EPS: NT$0.48 (up from NT$0.10 in FY 2023). Revenue: NT$1.22b (up 37% from FY 2023). Net income: NT$107.4m (up 382% from FY 2023). Profit margin: 8.8% (up from 2.5% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 115% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth.New Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. This is currently the only risk that has been identified for the company.お知らせ • Feb 26Orient Pharma Co., Ltd., Annual General Meeting, Jun 16, 2025Orient Pharma Co., Ltd., Annual General Meeting, Jun 16, 2025. Location: 13 floor no,128, sec.6 ch`eng to rd., beitou district, taipei city TaiwanValuation Update With 7 Day Price Move • Nov 12Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to NT$35.20, the stock trades at a trailing P/E ratio of 65.9x. Average trailing P/E is 25x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 106% over the past three years.New Risk • Nov 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Valuation Update With 7 Day Price Move • Oct 25Investor sentiment improves as stock rises 17%After last week's 17% share price gain to NT$31.00, the stock trades at a trailing P/E ratio of 58.1x. Average trailing P/E is 28x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 81% over the past three years.Buy Or Sell Opportunity • Oct 18Now 20% overvaluedOver the last 90 days, the stock has fallen 3.1% to NT$26.50. The fair value is estimated to be NT$22.05, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 31% over the last 3 years. Meanwhile, the company has become profitable.Buy Or Sell Opportunity • Sep 02Now 21% overvaluedOver the last 90 days, the stock has fallen 1.7% to NT$26.65. The fair value is estimated to be NT$22.05, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 31% over the last 3 years. Meanwhile, the company has become profitable.Reported Earnings • Apr 16Full year 2023 earnings released: EPS: NT$0.10 (vs NT$0.15 loss in FY 2022)Full year 2023 results: EPS: NT$0.10 (up from NT$0.15 loss in FY 2022). Revenue: NT$889.9m (up 74% from FY 2022). Net income: NT$22.3m (up NT$51.0m from FY 2022). Profit margin: 2.5% (up from net loss in FY 2022). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 86% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.お知らせ • Apr 04Orient Pharma Co., Ltd., Annual General Meeting, Jun 14, 2024Orient Pharma Co., Ltd., Annual General Meeting, Jun 14, 2024.New Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$237m free cash flow). Minor Risk Latest financial reports are more than 6 months old (reported June 2023 fiscal period end).New Risk • Aug 17New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NT$237m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$237m free cash flow). Minor Risk Shareholders have been diluted in the past year (19% increase in shares outstanding).Reported Earnings • Aug 13First half 2023 earnings releasedFirst half 2023 results: Revenue: NT$427.2m (up 45% from 1H 2022). Net income: NT$203.0k (down 99% from 1H 2022). Profit margin: 0% (down from 6.6% in 1H 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.Reported Earnings • Mar 19Full year 2022 earnings released: NT$0.15 loss per share (vs NT$0.55 loss in FY 2021)Full year 2022 results: NT$0.15 loss per share (improved from NT$0.55 loss in FY 2021). Revenue: NT$511.9m (up 11% from FY 2021). Net loss: NT$28.8m (loss narrowed 72% from FY 2021). Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Thomas Chen was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Aug 15First half 2022 earnings released: EPS: NT$0.10 (vs NT$0.33 loss in 1H 2021)First half 2022 results: EPS: NT$0.10 (up from NT$0.33 loss in 1H 2021). Revenue: NT$295.1m (up 62% from 1H 2021). Net income: NT$19.5m (up NT$81.3m from 1H 2021). Profit margin: 6.6% (up from net loss in 1H 2021). Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Thomas Chen was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Apr 03Full year 2021 earnings released: NT$0.55 loss per share (vs NT$1.01 loss in FY 2020)Full year 2021 results: NT$0.55 loss per share (up from NT$1.01 loss in FY 2020). Revenue: NT$463.3m (up 13% from FY 2020). Net loss: NT$102.7m (loss narrowed 40% from FY 2020). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.お知らせ • Mar 04Orient Pharma Co., Ltd., Annual General Meeting, Jun 30, 2022Orient Pharma Co., Ltd., Annual General Meeting, Jun 30, 2022.Reported Earnings • Apr 17Full year 2020 earnings released: NT$1.01 loss per share (vs NT$1.29 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: NT$412.0m (up 17% from FY 2019). Net loss: NT$171.4m (loss narrowed 15% from FY 2019). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.分析記事 • Mar 22Is Orient Pharma (GTSM:4166) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...お知らせ • Mar 19Orient Pharma Co., Ltd., Annual General Meeting, Jun 07, 2021Orient Pharma Co., Ltd., Annual General Meeting, Jun 07, 2021.分析記事 • Jan 28What Type Of Returns Would Orient Pharma's(GTSM:4166) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?Statistically speaking, long term investing is a profitable endeavour. But that doesn't mean long term investors can...Is New 90 Day High Low • Jan 27New 90-day low: NT$13.35The company is down 14% from its price of NT$15.50 on 30 October 2020. The Taiwanese market is up 21% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 16% over the same period.Reported Earnings • Jan 10Third quarter 2020 earnings released: NT$0.13 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: NT$116.3m (up 26% from 3Q 2019). Net loss: NT$23.6m (loss narrowed 38% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Jan 07New 90-day low: NT$14.30The company is down 16% from its price of NT$17.05 on 08 October 2020. The Taiwanese market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 15% over the same period.Is New 90 Day High Low • Dec 08New 90-day low: NT$14.45The company is down 20% from its price of NT$18.00 on 09 September 2020. The Taiwanese market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 11% over the same period.分析記事 • Dec 07Does Orient Pharma (GTSM:4166) Have A Healthy Balance Sheet?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Is New 90 Day High Low • Nov 02New 90-day low: NT$15.15The company is down 27% from its price of NT$20.80 on 04 August 2020. The Taiwanese market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 1.0% over the same period.Is New 90 Day High Low • Sep 25New 90-day low: NT$15.50The company is down 32% from its price of NT$22.75 on 24 June 2020. The Taiwanese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 4.0% over the same period.収支内訳Orient Pharma の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史TPEX:4166 収益、費用、利益 ( )TWD Millions日付収益収益G+A経費研究開発費31 Mar 261,4151974699531 Dec 251,4002084508030 Sep 251,2781284228830 Jun 251,2628041210831 Mar 251,26412038310231 Dec 241,22310739010430 Sep 241,13510736310030 Jun 241,0661193578431 Mar 24952603559331 Dec 238902234410030 Sep 23767-1327810730 Jun 23644-4821211531 Mar 23578-3814012231 Dec 22512-296812930 Sep 22544-256214630 Jun 22576-215616331 Mar 22520-625619131 Dec 21463-1035622030 Sep 21451-1705724230 Jun 21427-1735724231 Mar 21419-1725821331 Dec 20412-1715818430 Sep 20412-1626015530 Jun 20388-1776114231 Mar 20371-1896314831 Dec 19354-2016515430 Sep 19302-1686915730 Jun 19285-1767216531 Mar 19277-1687117631 Dec 18270-1606918630 Sep 18254-1856619630 Jun 18238-2106420731 Mar 18233-2376121031 Dec 17229-2655921430 Sep 17248-2365920830 Jun 17261-2146120331 Mar 17268-2076219731 Dec 16274-1996419230 Sep 16229-2235419530 Jun 16200-2334919331 Mar 16177-2354718731 Dec 15153-2374518230 Sep 15191-20346168質の高い収益: 4166は 高品質の収益 を持っています。利益率の向上: 4166の現在の純利益率 (13.9%)は、昨年(9.5%)よりも高くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: 4166過去 5 年間で収益を上げており、収益は年間74.9%増加しています。成長の加速: 4166の過去 1 年間の収益成長率 ( 63.9% ) は、5 年間の平均 ( 年間74.9%を下回っています。収益対業界: 4166の過去 1 年間の収益成長率 ( 63.9% ) はPharmaceuticals業界-9.2%を上回りました。株主資本利益率高いROE: 4166の 自己資本利益率 ( 7.6% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/31 19:35終値2026/07/31 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Orient Pharma Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • May 16First quarter 2026 earnings released: EPS: NT$0.17 (vs NT$0.23 in 1Q 2025)First quarter 2026 results: EPS: NT$0.17 (down from NT$0.23 in 1Q 2025). Revenue: NT$331.2m (up 4.5% from 1Q 2025). Net income: NT$38.7m (down 23% from 1Q 2025). Profit margin: 12% (down from 16% in 1Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 81% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Mar 14Full year 2025 earnings released: EPS: NT$0.90 (vs NT$0.48 in FY 2024)Full year 2025 results: EPS: NT$0.90 (up from NT$0.48 in FY 2024). Revenue: NT$1.40b (up 14% from FY 2024). Net income: NT$208.4m (up 94% from FY 2024). Profit margin: 15% (up from 8.8% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Nov 15Third quarter 2025 earnings released: EPS: NT$0.21 (vs NT$0.023 in 3Q 2024)Third quarter 2025 results: EPS: NT$0.21 (up from NT$0.023 in 3Q 2024). Revenue: NT$316.1m (up 2.0% from 3Q 2024). Net income: NT$47.3m (up NT$42.1m from 3Q 2024). Profit margin: 15% (up from 1.7% in 3Q 2024). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 93% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Aug 17Second quarter 2025 earnings released: EPS: NT$0.08 (vs NT$0.26 in 2Q 2024)Second quarter 2025 results: EPS: NT$0.08 (down from NT$0.26 in 2Q 2024). Revenue: NT$325.5m (flat on 2Q 2024). Net income: NT$18.8m (down 68% from 2Q 2024). Profit margin: 5.8% (down from 18% in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 99% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Jul 02First quarter 2025 earnings released: EPS: NT$0.23 (vs NT$0.22 in 1Q 2024)First quarter 2025 results: EPS: NT$0.23 (up from NT$0.22 in 1Q 2024). Revenue: NT$316.9m (up 5.1% from 1Q 2024). Net income: NT$50.6m (up 4.3% from 1Q 2024). Profit margin: 16% (in line with 1Q 2024). Over the last 3 years on average, earnings per share has increased by 109% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Mar 26Full year 2024 earnings released: EPS: NT$0.48 (vs NT$0.10 in FY 2023)Full year 2024 results: EPS: NT$0.48 (up from NT$0.10 in FY 2023). Revenue: NT$1.22b (up 37% from FY 2023). Net income: NT$107.4m (up 382% from FY 2023). Profit margin: 8.8% (up from 2.5% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 115% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth.
Reported Earnings • May 16First quarter 2026 earnings released: EPS: NT$0.17 (vs NT$0.23 in 1Q 2025)First quarter 2026 results: EPS: NT$0.17 (down from NT$0.23 in 1Q 2025). Revenue: NT$331.2m (up 4.5% from 1Q 2025). Net income: NT$38.7m (down 23% from 1Q 2025). Profit margin: 12% (down from 16% in 1Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 81% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Mar 14Full year 2025 earnings released: EPS: NT$0.90 (vs NT$0.48 in FY 2024)Full year 2025 results: EPS: NT$0.90 (up from NT$0.48 in FY 2024). Revenue: NT$1.40b (up 14% from FY 2024). Net income: NT$208.4m (up 94% from FY 2024). Profit margin: 15% (up from 8.8% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
お知らせ • Feb 26Orient Pharma Co., Ltd., Annual General Meeting, Jun 16, 2026Orient Pharma Co., Ltd., Annual General Meeting, Jun 16, 2026. Location: 13 floor no,128, sec.6 ch`eng to rd., beitou district, taipei city Taiwan
Reported Earnings • Nov 15Third quarter 2025 earnings released: EPS: NT$0.21 (vs NT$0.023 in 3Q 2024)Third quarter 2025 results: EPS: NT$0.21 (up from NT$0.023 in 3Q 2024). Revenue: NT$316.1m (up 2.0% from 3Q 2024). Net income: NT$47.3m (up NT$42.1m from 3Q 2024). Profit margin: 15% (up from 1.7% in 3Q 2024). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 93% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Sep 08Investor sentiment improves as stock rises 23%After last week's 23% share price gain to NT$28.25, the stock trades at a trailing P/E ratio of 79x. Average trailing P/E is 17x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 25% over the past three years.
New Risk • Sep 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.4% average weekly change). Profit margins are more than 30% lower than last year (6.3% net profit margin).
Valuation Update With 7 Day Price Move • Aug 22Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to NT$26.25, the stock trades at a trailing P/E ratio of 73.5x. Average trailing P/E is 16x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 19% over the past three years.
Reported Earnings • Aug 17Second quarter 2025 earnings released: EPS: NT$0.08 (vs NT$0.26 in 2Q 2024)Second quarter 2025 results: EPS: NT$0.08 (down from NT$0.26 in 2Q 2024). Revenue: NT$325.5m (flat on 2Q 2024). Net income: NT$18.8m (down 68% from 2Q 2024). Profit margin: 5.8% (down from 18% in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 99% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Jul 02First quarter 2025 earnings released: EPS: NT$0.23 (vs NT$0.22 in 1Q 2024)First quarter 2025 results: EPS: NT$0.23 (up from NT$0.22 in 1Q 2024). Revenue: NT$316.9m (up 5.1% from 1Q 2024). Net income: NT$50.6m (up 4.3% from 1Q 2024). Profit margin: 16% (in line with 1Q 2024). Over the last 3 years on average, earnings per share has increased by 109% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Jun 09Investor sentiment improves as stock rises 16%After last week's 16% share price gain to NT$36.95, the stock trades at a trailing P/E ratio of 76.8x. Average trailing P/E is 19x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 89% over the past three years.
New Risk • Apr 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 9.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.
Valuation Update With 7 Day Price Move • Apr 07Investor sentiment deteriorates as stock falls 26%After last week's 26% share price decline to NT$26.00, the stock trades at a trailing P/E ratio of 54x. Average trailing P/E is 18x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 31% over the past three years.
Reported Earnings • Mar 26Full year 2024 earnings released: EPS: NT$0.48 (vs NT$0.10 in FY 2023)Full year 2024 results: EPS: NT$0.48 (up from NT$0.10 in FY 2023). Revenue: NT$1.22b (up 37% from FY 2023). Net income: NT$107.4m (up 382% from FY 2023). Profit margin: 8.8% (up from 2.5% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 115% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth.
New Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. This is currently the only risk that has been identified for the company.
お知らせ • Feb 26Orient Pharma Co., Ltd., Annual General Meeting, Jun 16, 2025Orient Pharma Co., Ltd., Annual General Meeting, Jun 16, 2025. Location: 13 floor no,128, sec.6 ch`eng to rd., beitou district, taipei city Taiwan
Valuation Update With 7 Day Price Move • Nov 12Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to NT$35.20, the stock trades at a trailing P/E ratio of 65.9x. Average trailing P/E is 25x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 106% over the past three years.
New Risk • Nov 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Valuation Update With 7 Day Price Move • Oct 25Investor sentiment improves as stock rises 17%After last week's 17% share price gain to NT$31.00, the stock trades at a trailing P/E ratio of 58.1x. Average trailing P/E is 28x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 81% over the past three years.
Buy Or Sell Opportunity • Oct 18Now 20% overvaluedOver the last 90 days, the stock has fallen 3.1% to NT$26.50. The fair value is estimated to be NT$22.05, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 31% over the last 3 years. Meanwhile, the company has become profitable.
Buy Or Sell Opportunity • Sep 02Now 21% overvaluedOver the last 90 days, the stock has fallen 1.7% to NT$26.65. The fair value is estimated to be NT$22.05, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 31% over the last 3 years. Meanwhile, the company has become profitable.
Reported Earnings • Apr 16Full year 2023 earnings released: EPS: NT$0.10 (vs NT$0.15 loss in FY 2022)Full year 2023 results: EPS: NT$0.10 (up from NT$0.15 loss in FY 2022). Revenue: NT$889.9m (up 74% from FY 2022). Net income: NT$22.3m (up NT$51.0m from FY 2022). Profit margin: 2.5% (up from net loss in FY 2022). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 86% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.
お知らせ • Apr 04Orient Pharma Co., Ltd., Annual General Meeting, Jun 14, 2024Orient Pharma Co., Ltd., Annual General Meeting, Jun 14, 2024.
New Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$237m free cash flow). Minor Risk Latest financial reports are more than 6 months old (reported June 2023 fiscal period end).
New Risk • Aug 17New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NT$237m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$237m free cash flow). Minor Risk Shareholders have been diluted in the past year (19% increase in shares outstanding).
Reported Earnings • Aug 13First half 2023 earnings releasedFirst half 2023 results: Revenue: NT$427.2m (up 45% from 1H 2022). Net income: NT$203.0k (down 99% from 1H 2022). Profit margin: 0% (down from 6.6% in 1H 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Mar 19Full year 2022 earnings released: NT$0.15 loss per share (vs NT$0.55 loss in FY 2021)Full year 2022 results: NT$0.15 loss per share (improved from NT$0.55 loss in FY 2021). Revenue: NT$511.9m (up 11% from FY 2021). Net loss: NT$28.8m (loss narrowed 72% from FY 2021). Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Thomas Chen was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Aug 15First half 2022 earnings released: EPS: NT$0.10 (vs NT$0.33 loss in 1H 2021)First half 2022 results: EPS: NT$0.10 (up from NT$0.33 loss in 1H 2021). Revenue: NT$295.1m (up 62% from 1H 2021). Net income: NT$19.5m (up NT$81.3m from 1H 2021). Profit margin: 6.6% (up from net loss in 1H 2021). Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Thomas Chen was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Apr 03Full year 2021 earnings released: NT$0.55 loss per share (vs NT$1.01 loss in FY 2020)Full year 2021 results: NT$0.55 loss per share (up from NT$1.01 loss in FY 2020). Revenue: NT$463.3m (up 13% from FY 2020). Net loss: NT$102.7m (loss narrowed 40% from FY 2020). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.
お知らせ • Mar 04Orient Pharma Co., Ltd., Annual General Meeting, Jun 30, 2022Orient Pharma Co., Ltd., Annual General Meeting, Jun 30, 2022.
Reported Earnings • Apr 17Full year 2020 earnings released: NT$1.01 loss per share (vs NT$1.29 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: NT$412.0m (up 17% from FY 2019). Net loss: NT$171.4m (loss narrowed 15% from FY 2019). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
分析記事 • Mar 22Is Orient Pharma (GTSM:4166) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
お知らせ • Mar 19Orient Pharma Co., Ltd., Annual General Meeting, Jun 07, 2021Orient Pharma Co., Ltd., Annual General Meeting, Jun 07, 2021.
分析記事 • Jan 28What Type Of Returns Would Orient Pharma's(GTSM:4166) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?Statistically speaking, long term investing is a profitable endeavour. But that doesn't mean long term investors can...
Is New 90 Day High Low • Jan 27New 90-day low: NT$13.35The company is down 14% from its price of NT$15.50 on 30 October 2020. The Taiwanese market is up 21% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 16% over the same period.
Reported Earnings • Jan 10Third quarter 2020 earnings released: NT$0.13 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: NT$116.3m (up 26% from 3Q 2019). Net loss: NT$23.6m (loss narrowed 38% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Jan 07New 90-day low: NT$14.30The company is down 16% from its price of NT$17.05 on 08 October 2020. The Taiwanese market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 15% over the same period.
Is New 90 Day High Low • Dec 08New 90-day low: NT$14.45The company is down 20% from its price of NT$18.00 on 09 September 2020. The Taiwanese market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 11% over the same period.
分析記事 • Dec 07Does Orient Pharma (GTSM:4166) Have A Healthy Balance Sheet?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Is New 90 Day High Low • Nov 02New 90-day low: NT$15.15The company is down 27% from its price of NT$20.80 on 04 August 2020. The Taiwanese market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 1.0% over the same period.
Is New 90 Day High Low • Sep 25New 90-day low: NT$15.50The company is down 32% from its price of NT$22.75 on 24 June 2020. The Taiwanese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 4.0% over the same period.